Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06068543 · ClinicalTrials.gov registry record · Phase 2
Reducing Frailty for Older Cancer Survivors Using Supplements II
A Phase 2 study of Inflammation and Frailty, sponsored by University of Rochester.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 118
- Enrollment target
- 1
- Study location
NCT06068543 is a Phase 2 study of Inflammation and Frailty that is actively recruiting participants, run by University of Rochester. The registered enrollment target is 118 participants, below the 287-participant average among 132 other Inflammation trials with a reported enrollment target (59% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06068543, a Phase 2 study of Inflammation and Frailty, is actively recruiting participants, sponsored by University of Rochester.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 118 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is a two-arm placebo controlled randomized clinical trial, to assess the effect of a 12-week EGCG intervention on physical frailty compared to placebo in pre-frail older cancer survivors.
Conditions Studied
Interventions
- DRUG Epigallocatechin-3-Gallate (EGCG)
- DRUG Microcrystalline cellulose (MCC)
- DIETARY_SUPPLEMENT Ascorbic Acid (Vitamin C)
Study Locations (1)
New York
- University of Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2024-10-25 |
| Est. Completion | 2030-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06068543
The ClinicalTrials.gov registry entry for NCT06068543 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 118 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 287-participant average among 132 other Inflammation trials with a reported enrollment target (59% lower). The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Inflammation appearing as the primary indexed condition, and to 3 interventions - of which Epigallocatechin-3-Gallate (EGCG) is the first listed.
NCT06068543 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06068543 about?
NCT06068543 is a clinical study titled "Reducing Frailty for Older Cancer Survivors Using Supplements II". This study is a two-arm placebo controlled randomized clinical trial, to assess the effect of a 12-week EGCG intervention on physical frailty compared to placebo in pre-frail older cancer survivors.
What is the current status of trial NCT06068543?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 118 participants. The study started on 2024-10-25. Estimated completion is 2030-12-31.
What conditions does trial NCT06068543 study?
This clinical trial studies the following conditions: Inflammation, Frailty.
What interventions are being tested in trial NCT06068543?
The interventions under investigation include: Epigallocatechin-3-Gallate (EGCG) (DRUG), Microcrystalline cellulose (MCC) (DRUG), Ascorbic Acid (Vitamin C) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06068543?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06068543 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Inflammation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Focused Orticumab Research for Treating Inflammation in Coronary Arteries
RECRUITING · Phase 2
-
Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab
RECRUITING · Phase 2
-
Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1
RECRUITING · Phase 2
-
Modulating Exercise Dosage to Improve Concussion Recovery
RECRUITING · Phase 2
-
Passive Stretching in Peripheral Arterial Disease Patients
RECRUITING · Phase 2
-
Clinical Trial of the Seaweed Supplement Fucoidan in Survivors of Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.